Portugal's medicines regulator, which also runs the national health technology assessment system, SiNATS. A cancer medicine authorised for the whole EU still needs a SiNATS assessment before NHS hospitals may buy it or the state may reimburse it.
INFARMED, the Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., is the public institute that regulates medicines, medical devices and clinical trials in Portugal. New cancer medicines are authorised once for the whole European Union through the European Medicines Agency's centralised procedure.
Decree-Law 97/2015 of 1 June 2015 created the Sistema Nacional de Avaliação de Tecnologias de Saúde (SiNATS), managed by INFARMED, covering every public and private body that produces, sells or uses health technologies, with technical, therapeutic and economic assessment. Its preamble states that placing a technology on the market is a necessary but not sufficient condition for NHS funding, and it introduced contracts with the marketing authorisation holder as the instrument for reimbursement (comparticipação) and for the prior assessment (avaliação prévia) that every prescription medicine NHS bodies are to buy must pass, which weighs therapeutic innovation against economic advantage and sets a maximum purchase price. Law 53/2017 links the national cancer registry to INFARMED for monitoring the effectiveness of medicines in use. The OECD and European Commission's 2025 profile reports a mean of 748 days from EMA approval to a coverage decision for a sample of breast and lung cancer medicines, 45% longer than the EU average, and 266 days for cancer biosimilars against an EU average of 505; it also cites INFARMED's figures of 203 clinical trials approved in 2023, against 99 in 2012, 58 of them for antineoplastic and immunomodulatory drugs.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-11-19.
Matched to Infarmed, including child institutions. 4 works · 38 citations · 100% open access · 25% clinical trials · 0% reviews.
| Work | Journal | Year | Citations |
|---|---|---|---|
| Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study 10.1016/j.breast.2022.02.005 · open access | The Breast | 2022 | 17 |
| Advancing rare disease treatment: EMA’s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation 10.1038/s41434-024-00446-0 · open access | Gene Therapy | 2024 | 12 |
| Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice 10.1186/s13058-023-01678-5 · open access | Breast Cancer Research | 2023 | 8 |
| Age and Clinical Outcomes of Immune Checkpoint Inhibitor Toxicities in Portugal: A Decade of Pharmacovigilance 10.3390/cancers18010076 · open access | Cancers | 2025 | 1 |
Shares Portuguese National Health Service (Serviço Nacional de Saúde), Portuguese National Cancer Registry (Registo Oncológico Nacional).
Shares Portuguese National Health Service (Serviço Nacional de Saúde), Portuguese National Cancer Registry (Registo Oncológico Nacional).
Shares Portuguese National Health Service (Serviço Nacional de Saúde), Portuguese National Cancer Registry (Registo Oncológico Nacional).
Shares Portuguese National Health Service (Serviço Nacional de Saúde), Portuguese National Cancer Registry (Registo Oncológico Nacional).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/